BrainSustain For Kids Vanilla Delight
Withdrawn from the US market on 11 November 2014 (according to the DSLD)
XYMOGEN EP, food supplement from the US market
Label withdrawn from the US market. BrainSustain For Kids Vanilla Delight (XYMOGEN EP), a food supplement without a usable barcode in DSLD, is described by its US market label. If sold in France, it would be subject to 1 point of French or European regulation, detailed below. The formula sold in Europe under the same name may differ.
Official label. Dietary Supplement Label Database (DSLD), US National Institutes of Health: current and off-market labels, retrieved 27 October 2026.
Source: NIH Office of Dietary Supplements, Dietary Supplement Label Database (CC0); US market labels.
If this product were sold in France
- Conditions légales
Brassica oleracea L.: L'étiquetage doit comporter un avertissement recommandant aux personnes ayant une hypothyroïdie ou un traitement de la thyroïde de consulter leur médecin.
Source: French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, arrêté du 24 juin 2014, annexe I.
A daily dose is calculated only if the label gives the maximum number of servings and a unit of mass (or international units for vitamin D). Quantities come from the label, not an analysis. In the United States, the label presents this product as a ‘dietary supplement’; in France, a product of this type may belong to another category (a sports powder, for example), and maximum food supplement doses do not apply to it.
Label composition
- Brand
- XYMOGEN EP
- Barcode
- Not provided or invalid in DSLD
- Form
- Powder
- One serving
- 20 g
- Servings
- up to 1 serving per day
- Other ingredients (in English, as written)
- VegaPro(TM), evaporated Cane, Sunflower Oil, Sunflower Oil, Inulin Fiber, Natural flavors, Medium Chain Triglycerides, Potassium Citrate, Xanthan Gum, Guar Gum, Sodium Chloride, Sodium Citrate, Stevia
| Ingredient (as written, in English) | Category | Per serving |
|---|---|---|
| Calories | Other | 80 kcal |
| Calories from Fat | Other | 15 kcal |
| Total Fat | Fat | 1.5 g |
| Saturated Fat | Fat | 0 g |
| Cholesterol | Fat | 0 mg |
| Sodium | Mineral | 100 mg |
| Potassium | Mineral | 60 mg |
| Total Carbohydrates | Carbohydrate | 10 g |
| Dietary Fiber | Fibre | 1 g |
| Soluble Fiber | Fibre | 1 g |
| Sugar | Carbohydrate | 6 g |
| Protein | Protein | 6 g |
| N-Acetyl-Cysteine | Other substance | 100 mg |
| Phosphatidylserine | Fat | 25 mg |
| Alpha Lipoic Acid | Other substance | 20 mg |
| Coenzyme Q10 | Other substance | 50 mg |
| Broccoli Seed Extract (Brassica oleracea) | Plant | 273 mg |
| Docosahexaenoic Acid | Fatty acid | 50 mg |
Displayed label: Official label. Labels on the market are prioritised, followed by the most recent for the same status.
This information reproduces the US label recorded by the US National Institutes of Health (NIH). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.
Official warnings (Health Canada)
Health Canada publishes warnings on these ingredients:
- Phosphatidylserine
Read the warning, when it applies and the studies cited
- Coenzyme Q10
Read the warning, when it applies and the studies cited
Coenzyme Q10 (UBIQUINONE-10)
Route of administration: Oral
Cautions and warnings
Condition of application: All products.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood pressure medication (Rosenfeldt et al. 2007; Singh et al. 1999).
Sources cited by Health Canada (2)
- Rosenfeldt FL, Haas SJ, Krum H, Hadj A, Ng K, Leong JY, Watts GF. Coenzyme Q10 in the treatment of hypertension: a meta-analysis of the clinical trials. Journal of Human Hypertension 2007;21(4):297-306. PubMed Meta-analysis
- Singh RB, Niaz MA, Rastogi SS, Shukla PK, Thakur AS. Effect of hydrosoluble coenzyme Q10 on blood pressures and insulin resistance in hypertensive patients with coronary artery disease. Journal of Human Hypertension 1999;13(3):203-208. PubMed Randomised trial
Applies to products providing more than 100 mg of Coenzyme Q10 per day.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners (Engelsen et al. 2003; Landbo and Almdal 1998; Spigset 1994).
Sources cited by Health Canada (3)
- Engelsen J, Nielsen JD, Hansen KF. [Effect of coenzyme Q10 and Ginkgo biloba on warfarin dosage in patients on long-term warfarin treatment. A randomized, double-blind, placebo-controlled cross-over trial]. Ugeskr Laeger 2003;165(18):1868-1871 (in Danish). PubMed Randomised trial
- Landbo C, Almdal TP. [Interaction between warfarin and coenzyme Q10]. Ugeskr Laeger 1998;160(22):3226-3227 (in Danish). PubMed Case report
- Spigset O. Reduced effect of warfarin caused by ubidecarenone. Lancet 1994;344(8933):1372-1373. PubMed Case report
Condition of application: Migraine prophylaxis/prevention.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if migraine frequency increases and associated nausea and vomiting persist or worsen.
They concern the ingredient, not this product or its dose. They do not replace medical advice.
List declared on (register: Dietary Supplement Label Database (DSLD), US National Institutes of Health: current and off-market labels).
Brand : XYMOGEN EP
Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.
Cite this page: CompoAtlas, “BrainSustain For Kids Vanilla Delight : étiquette retirée du marché américain (XYMOGEN EP): composition and French regulation”, https://compoatlas.com/en/supplements/us-labels/dsld-6604-brainsustain-for-kids-vanilla-delight-xymogen-ep, updated 11 November 2014.